New drug trial targets rare kidney diseases

NCT ID NCT06989359

Summary

This study is testing an experimental drug called ADX-038 for people with specific immune-related kidney diseases. Researchers will enroll 45 adults with conditions like IgA nephropathy or C3 glomerulopathy to see if the drug is safe and helps control their kidney disease. The goal is to reduce disease activity and protect kidney function over time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGAN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ADARx Clinical Site

    RECRUITING

    Shreveport, Louisiana, 71101, United States

  • ADARx Clinical Site

    RECRUITING

    Shelby, Michigan, 48066, United States

  • ADARx Clinical Site

    RECRUITING

    Dakota Dunes, South Dakota, 57049, United States

  • ADARx Clinical Site

    RECRUITING

    Dallas, Texas, 75230, United States

  • ADARx Clinical Site

    RECRUITING

    Houston, Texas, 77027, United States

  • ADARx Clinical Site

    RECRUITING

    Wollongong, New South Wales, 2500, Australia

  • ADARx Clinical Site

    RECRUITING

    Pok Fu Lam, 2500, Hong Kong

  • ADARx Clinical Site

    RECRUITING

    Shatin, Hong Kong

  • ADARx Clinical Site

    RECRUITING

    Gyeonggi-do, New South Wales, 05278, South Korea

  • ADARx Clinical Site

    RECRUITING

    Seoul, New South Wales, 03080, South Korea

  • ADARx Clinical Site

    RECRUITING

    Cheonan, 31151, South Korea

  • ADARx Clinical Site

    RECRUITING

    Seoul, 03722, South Korea

Conditions

Explore the condition pages connected to this study.